Trial Profile
Atomoxetine and rivastigmine and its effects on attention in patients with non-demented Parkinson's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2013
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary) ; Atomoxetine
- Indications Parkinson's disease
- Focus Therapeutic Use
- 31 Jul 2013 New trial record
- 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.